Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
Clinical trial NCT02112838 · COMPLETED
Trial details
- NCT number
- NCT02112838
- Sponsor
- Rigel Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2018-03-23
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.